Seres Therapeutics Inc Asset Resilience Ratio
Seres Therapeutics Inc asset resilience ratio. Seres Therapeutics Inc (MCRB) has an Asset Resilience Ratio of 0.00% as of December 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Seres Therapeutics Inc liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Seres Therapeutics Inc (2015–2023)
Asset resilience ratio of Seres Therapeutics Inc from 2015 to 2023. This chart shows how Seres Therapeutics Inc's Asset Resilience Ratio has changed over time. Read MCRB liabilities breakdown for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Seres Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Seres Therapeutics Inc assets under control.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Seres Therapeutics Inc maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Seres Therapeutics Inc Industry Peers by Asset Resilience Ratio
Compare Seres Therapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL |
Biotechnology | 1.36% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA |
Biotechnology | 53.11% |
|
Gempharmatech Co. Ltd. A
SHG:688046 |
Biotechnology | 23.95% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 74.48% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
|
Guangdong VTR Bio-Tech Co Ltd
SHE:300381 |
Biotechnology | 4.98% |
Seres Therapeutics Inc Asset Resilience Ratio by Year (2015–2023)
Seres Therapeutics Inc asset resilience ratio by year from 2015 to 2023. The table below shows the annual Asset Resilience Ratio data for Seres Therapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | 0.00% | $0.00 | $358.60 Million | -- |
| 2022-12-31 | 5.25% | $18.31 Million | $348.78 Million | -25.95pp |
| 2021-12-31 | 31.20% | $110.70 Million | $354.86 Million | -8.92pp |
| 2020-12-31 | 40.11% | $137.57 Million | $342.94 Million | +17.70pp |
| 2019-12-31 | 22.42% | $29.69 Million | $132.44 Million | -- |
| 2018-12-31 | 0.00% | $0.00 | $120.47 Million | -- |
| 2017-12-31 | 60.10% | $113.89 Million | $189.52 Million | +9.22pp |
| 2016-12-31 | 50.87% | $138.70 Million | $272.65 Million | -9.59pp |
| 2015-12-31 | 60.47% | $131.15 Million | $216.90 Million | -- |
About Seres Therapeutics Inc
Seres Therapeutics, Inc., a clinical-stage company, focuses on developing biotherapeutics for serious diseases. The company develops SER-155, an investigational oral live biotherapeutic to decolonize GI pathogens, enhance GI epithelial barrier integrity, and regulate immune response to prevent bacterial bloodstream infections, as well as other pathogen-associated negative clinical outcomes in pat… Read more